Andere Sprachen ACADIA Pharmaceuticals Inc.

Aktien

603035

US0042251084

ACAD

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 15.12.2025			% 5 Tage	Veränd. 1. Jan.
27.26 ^USD	+0.41%		+1.87%	+48.56%

15.12.	Neuren Pharmaceuticals gibt bekannt, dass sein an der Nasdaq notierter Partner die US-Zulassung der FDA für eine Lösung zum Einnehmen erhalten hat; Aktien steigen um 3 %	MT
12.12.	Acadia Pharmaceuticals Inc. gibt FDA-Zulassung für Daybue® STIX (Trofinetid) als orale Lösung bekannt, eine neue Pulverformulierung von Trofinetid zur Behandlung des Rett-Syndroms	CI

Andere Sprachen

Neuren Pharmaceuticals Says Nasdaq-Listed Partner Receives US FDA Approval for Oral Solution; Shares Up 3%	15.12.
Acadia Pharmaceuticals Inc. Announces FDA Approval of Daybue®? STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome	12.12.
Acadia Pharmaceuticals Gets FDA Approval for Powder Treatment for Rett Syndrome	12.12.
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome	12.12.
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference	20.11.
ACADIA Pharmaceuticals : Jefferies London Healthcare Conference Presentation	18.11.
Neuren Pharmaceuticals Says Rett Syndrome Drug Posts Higher Q3 Net Sales; Shares Down 9%	06.11.
Acadia Phramaceuticals Q3 revenue rises, lifts 2025 revenue guidance	05.11.
Earnings Flash (ACAD) Acadia Pharmaceuticals Inc. Reports Q3 Revenue $278.6M, vs. FactSet Est of $276.5M	05.11.
ACADIA Pharmaceuticals : 3Q25 Earnings Presentation	05.11.
Acadia Pharmaceuticals Continues to Seek Acquisitions	05.11.
Acadia: Q3 Earnings Snapshot	05.11.
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview	05.11.
ACADIA Pharmaceuticals Inc. Updates Earnings Guidance for the Full Year 2025	05.11.
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	05.11.
ACADIA Pharmaceuticals Inc. Announces Resignation of Daniel B. Soland from the Board and from His Positions as A Member and Chair of the Nominating and Corporate Governance Committee of the Board, Effective as of October 30, 2025	03.11.
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences	28.10.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD	28.10.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD	23.10.
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights	22.10.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD	18.10.
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025	15.10.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD	13.10.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD	08.10.
Acadia Healthcare Company, Inc. Announces Chief Financial Officer Changes, Effective October 27, 2025	07.10.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ACADIA Pharmaceuticals Inc.

Aktien

603035

US0042251084

ACAD

Biotechnologie

Andere Sprachen

Filter